nodes	percent_of_prediction	percent_of_DWPC	metapath
Torasemide—CYP2C19—Teniposide—lymphatic system cancer	0.199	0.546	CbGbCtD
Torasemide—CYP2C9—Teniposide—lymphatic system cancer	0.166	0.454	CbGbCtD
Torasemide—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.0139	0.0218	CcSEcCtD
Torasemide—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.0131	0.0206	CcSEcCtD
Torasemide—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.01	0.0158	CcSEcCtD
Torasemide—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00997	0.0157	CcSEcCtD
Torasemide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00943	0.0149	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00934	0.0147	CcSEcCtD
Torasemide—Dehydration—Fludarabine—lymphatic system cancer	0.00869	0.0137	CcSEcCtD
Torasemide—Hyperuricaemia—Vincristine—lymphatic system cancer	0.00847	0.0133	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00841	0.0132	CcSEcCtD
Torasemide—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.00825	0.013	CcSEcCtD
Torasemide—Blood uric acid increased—Vincristine—lymphatic system cancer	0.008	0.0126	CcSEcCtD
Torasemide—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.0078	0.0123	CcSEcCtD
Torasemide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00777	0.0122	CcSEcCtD
Torasemide—Haemoglobin—Teniposide—lymphatic system cancer	0.00739	0.0116	CcSEcCtD
Torasemide—Haemorrhage—Teniposide—lymphatic system cancer	0.00735	0.0116	CcSEcCtD
Torasemide—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00728	0.0115	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00714	0.0112	CcSEcCtD
Torasemide—Arthritis—Bleomycin—lymphatic system cancer	0.00705	0.0111	CcSEcCtD
Torasemide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00694	0.0109	CcSEcCtD
Torasemide—Haemoglobin—Fludarabine—lymphatic system cancer	0.00649	0.0102	CcSEcCtD
Torasemide—Haemorrhage—Fludarabine—lymphatic system cancer	0.00646	0.0102	CcSEcCtD
Torasemide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00611	0.00962	CcSEcCtD
Torasemide—Hyponatraemia—Carmustine—lymphatic system cancer	0.006	0.00945	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00598	0.00942	CcSEcCtD
Torasemide—Hyponatraemia—Vincristine—lymphatic system cancer	0.00573	0.00903	CcSEcCtD
Torasemide—Leukopenia—Teniposide—lymphatic system cancer	0.00573	0.00902	CcSEcCtD
Torasemide—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00558	0.00879	CcSEcCtD
Torasemide—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00556	0.00875	CcSEcCtD
Torasemide—Chest pain—Teniposide—lymphatic system cancer	0.00545	0.00858	CcSEcCtD
Torasemide—Hypokalaemia—Carmustine—lymphatic system cancer	0.00544	0.00857	CcSEcCtD
Torasemide—Dehydration—Vincristine—lymphatic system cancer	0.00531	0.00836	CcSEcCtD
Torasemide—Oedema—Teniposide—lymphatic system cancer	0.00522	0.00823	CcSEcCtD
Torasemide—Dehydration—Mitoxantrone—lymphatic system cancer	0.00517	0.00814	CcSEcCtD
Torasemide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00511	0.00806	CcSEcCtD
Torasemide—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00506	0.00797	CcSEcCtD
Torasemide—Leukopenia—Fludarabine—lymphatic system cancer	0.00503	0.00793	CcSEcCtD
Torasemide—Cough—Fludarabine—lymphatic system cancer	0.00491	0.00773	CcSEcCtD
Torasemide—Hypotension—Teniposide—lymphatic system cancer	0.00488	0.00769	CcSEcCtD
Torasemide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00485	0.00764	CcSEcCtD
Torasemide—Arthralgia—Fludarabine—lymphatic system cancer	0.00479	0.00754	CcSEcCtD
Torasemide—Myalgia—Fludarabine—lymphatic system cancer	0.00479	0.00754	CcSEcCtD
Torasemide—Haemoglobin—Bleomycin—lymphatic system cancer	0.00476	0.0075	CcSEcCtD
Torasemide—Haemorrhage—Bleomycin—lymphatic system cancer	0.00474	0.00746	CcSEcCtD
Torasemide—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00466	0.00734	CcSEcCtD
Torasemide—Oedema—Fludarabine—lymphatic system cancer	0.00459	0.00723	CcSEcCtD
Torasemide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00454	0.00716	CcSEcCtD
Torasemide—Vomiting—Mechlorethamine—lymphatic system cancer	0.0045	0.0071	CcSEcCtD
Torasemide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00449	0.00708	CcSEcCtD
Torasemide—Rash—Mechlorethamine—lymphatic system cancer	0.00447	0.00704	CcSEcCtD
Torasemide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00446	0.00703	CcSEcCtD
Torasemide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00442	0.00697	CcSEcCtD
Torasemide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00433	0.00683	CcSEcCtD
Torasemide—Nausea—Mechlorethamine—lymphatic system cancer	0.00421	0.00663	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00418	0.00659	CcSEcCtD
Torasemide—Haemoglobin—Carmustine—lymphatic system cancer	0.00416	0.00655	CcSEcCtD
Torasemide—Haemorrhage—Carmustine—lymphatic system cancer	0.00414	0.00651	CcSEcCtD
Torasemide—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00411	0.00648	CcSEcCtD
Torasemide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00404	0.00637	CcSEcCtD
Torasemide—Constipation—Fludarabine—lymphatic system cancer	0.00393	0.00618	CcSEcCtD
Torasemide—Pain—Fludarabine—lymphatic system cancer	0.00393	0.00618	CcSEcCtD
Torasemide—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00388	0.00612	CcSEcCtD
Torasemide—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00386	0.00609	CcSEcCtD
Torasemide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00385	0.00607	CcSEcCtD
Torasemide—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00384	0.00606	CcSEcCtD
Torasemide—Asthenia—Teniposide—lymphatic system cancer	0.00375	0.0059	CcSEcCtD
Torasemide—Leukopenia—Bleomycin—lymphatic system cancer	0.00369	0.00582	CcSEcCtD
Torasemide—Cough—Bleomycin—lymphatic system cancer	0.0036	0.00567	CcSEcCtD
Torasemide—Diarrhoea—Teniposide—lymphatic system cancer	0.00357	0.00563	CcSEcCtD
Torasemide—Chest pain—Bleomycin—lymphatic system cancer	0.00351	0.00553	CcSEcCtD
Torasemide—Myalgia—Bleomycin—lymphatic system cancer	0.00351	0.00553	CcSEcCtD
Torasemide—Oedema—Bleomycin—lymphatic system cancer	0.00337	0.0053	CcSEcCtD
Torasemide—Vomiting—Teniposide—lymphatic system cancer	0.00332	0.00523	CcSEcCtD
Torasemide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0033	0.00519	CcSEcCtD
Torasemide—Asthenia—Fludarabine—lymphatic system cancer	0.00329	0.00519	CcSEcCtD
Torasemide—Rash—Teniposide—lymphatic system cancer	0.00329	0.00519	CcSEcCtD
Torasemide—Dermatitis—Teniposide—lymphatic system cancer	0.00329	0.00518	CcSEcCtD
Torasemide—Headache—Teniposide—lymphatic system cancer	0.00327	0.00515	CcSEcCtD
Torasemide—Leukopenia—Carmustine—lymphatic system cancer	0.00322	0.00508	CcSEcCtD
Torasemide—Hypotension—Bleomycin—lymphatic system cancer	0.00314	0.00495	CcSEcCtD
Torasemide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00314	0.00495	CcSEcCtD
Torasemide—Nausea—Teniposide—lymphatic system cancer	0.0031	0.00489	CcSEcCtD
Torasemide—Leukopenia—Vincristine—lymphatic system cancer	0.00308	0.00485	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00307	0.00483	CcSEcCtD
Torasemide—Chest pain—Carmustine—lymphatic system cancer	0.00306	0.00483	CcSEcCtD
Torasemide—Myalgia—Carmustine—lymphatic system cancer	0.00306	0.00483	CcSEcCtD
Torasemide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.003	0.00472	CcSEcCtD
Torasemide—Oedema—Carmustine—lymphatic system cancer	0.00294	0.00463	CcSEcCtD
Torasemide—Myalgia—Vincristine—lymphatic system cancer	0.00293	0.00461	CcSEcCtD
Torasemide—Cough—Mitoxantrone—lymphatic system cancer	0.00292	0.0046	CcSEcCtD
Torasemide—Vomiting—Fludarabine—lymphatic system cancer	0.00292	0.0046	CcSEcCtD
Torasemide—Rash—Fludarabine—lymphatic system cancer	0.00289	0.00456	CcSEcCtD
Torasemide—Dermatitis—Fludarabine—lymphatic system cancer	0.00289	0.00456	CcSEcCtD
Torasemide—Pain—Bleomycin—lymphatic system cancer	0.00288	0.00453	CcSEcCtD
Torasemide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00288	0.00453	CcSEcCtD
Torasemide—Headache—Fludarabine—lymphatic system cancer	0.00288	0.00453	CcSEcCtD
Torasemide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00285	0.00449	CcSEcCtD
Torasemide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00285	0.00449	CcSEcCtD
Torasemide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00285	0.00449	CcSEcCtD
Torasemide—Oedema—Vincristine—lymphatic system cancer	0.0028	0.00442	CcSEcCtD
Torasemide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00275	0.00433	CcSEcCtD
Torasemide—Hypotension—Carmustine—lymphatic system cancer	0.00275	0.00432	CcSEcCtD
Torasemide—Oedema—Mitoxantrone—lymphatic system cancer	0.00273	0.0043	CcSEcCtD
Torasemide—Nausea—Fludarabine—lymphatic system cancer	0.00273	0.0043	CcSEcCtD
Torasemide—Shock—Mitoxantrone—lymphatic system cancer	0.00269	0.00423	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00268	0.00422	CcSEcCtD
Torasemide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00267	0.00421	CcSEcCtD
Torasemide—Insomnia—Carmustine—lymphatic system cancer	0.00266	0.00419	CcSEcCtD
Torasemide—Hypotension—Vincristine—lymphatic system cancer	0.00262	0.00413	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00256	0.00403	CcSEcCtD
Torasemide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00255	0.00402	CcSEcCtD
Torasemide—Insomnia—Vincristine—lymphatic system cancer	0.00254	0.004	CcSEcCtD
Torasemide—Pain—Carmustine—lymphatic system cancer	0.00251	0.00396	CcSEcCtD
Torasemide—Constipation—Carmustine—lymphatic system cancer	0.00251	0.00396	CcSEcCtD
Torasemide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00249	0.00393	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00249	0.00392	CcSEcCtD
Torasemide—Asthenia—Bleomycin—lymphatic system cancer	0.00241	0.0038	CcSEcCtD
Torasemide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0024	0.00379	CcSEcCtD
Torasemide—Pain—Vincristine—lymphatic system cancer	0.0024	0.00378	CcSEcCtD
Torasemide—Constipation—Vincristine—lymphatic system cancer	0.0024	0.00378	CcSEcCtD
Torasemide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00235	0.0037	CcSEcCtD
Torasemide—Pain—Mitoxantrone—lymphatic system cancer	0.00234	0.00368	CcSEcCtD
Torasemide—Constipation—Mitoxantrone—lymphatic system cancer	0.00234	0.00368	CcSEcCtD
Torasemide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.0022	0.00347	CcSEcCtD
Torasemide—Vomiting—Bleomycin—lymphatic system cancer	0.00214	0.00337	CcSEcCtD
Torasemide—Rash—Bleomycin—lymphatic system cancer	0.00212	0.00334	CcSEcCtD
Torasemide—Dermatitis—Bleomycin—lymphatic system cancer	0.00212	0.00334	CcSEcCtD
Torasemide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00212	0.00333	CcSEcCtD
Torasemide—Asthenia—Carmustine—lymphatic system cancer	0.00211	0.00332	CcSEcCtD
Torasemide—Asthenia—Vincristine—lymphatic system cancer	0.00201	0.00317	CcSEcCtD
Torasemide—Diarrhoea—Carmustine—lymphatic system cancer	0.00201	0.00317	CcSEcCtD
Torasemide—Nausea—Bleomycin—lymphatic system cancer	0.002	0.00315	CcSEcCtD
Torasemide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00196	0.00309	CcSEcCtD
Torasemide—Dizziness—Carmustine—lymphatic system cancer	0.00194	0.00306	CcSEcCtD
Torasemide—Haemoglobin—Methotrexate—lymphatic system cancer	0.00193	0.00303	CcSEcCtD
Torasemide—Diarrhoea—Vincristine—lymphatic system cancer	0.00192	0.00302	CcSEcCtD
Torasemide—Haemorrhage—Methotrexate—lymphatic system cancer	0.00192	0.00302	CcSEcCtD
Torasemide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00187	0.00294	CcSEcCtD
Torasemide—Vomiting—Carmustine—lymphatic system cancer	0.00187	0.00294	CcSEcCtD
Torasemide—Dizziness—Vincristine—lymphatic system cancer	0.00185	0.00292	CcSEcCtD
Torasemide—Rash—Carmustine—lymphatic system cancer	0.00185	0.00292	CcSEcCtD
Torasemide—Dermatitis—Carmustine—lymphatic system cancer	0.00185	0.00292	CcSEcCtD
Torasemide—Headache—Carmustine—lymphatic system cancer	0.00184	0.0029	CcSEcCtD
Torasemide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00181	0.00285	CcSEcCtD
Torasemide—Vomiting—Vincristine—lymphatic system cancer	0.00178	0.00281	CcSEcCtD
Torasemide—Rash—Vincristine—lymphatic system cancer	0.00177	0.00279	CcSEcCtD
Torasemide—Dermatitis—Vincristine—lymphatic system cancer	0.00177	0.00278	CcSEcCtD
Torasemide—Headache—Vincristine—lymphatic system cancer	0.00176	0.00277	CcSEcCtD
Torasemide—Nausea—Carmustine—lymphatic system cancer	0.00175	0.00275	CcSEcCtD
Torasemide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00174	0.00274	CcSEcCtD
Torasemide—Rash—Mitoxantrone—lymphatic system cancer	0.00172	0.00271	CcSEcCtD
Torasemide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00172	0.00271	CcSEcCtD
Torasemide—Headache—Mitoxantrone—lymphatic system cancer	0.00171	0.0027	CcSEcCtD
Torasemide—Nausea—Vincristine—lymphatic system cancer	0.00167	0.00262	CcSEcCtD
Torasemide—Nausea—Mitoxantrone—lymphatic system cancer	0.00162	0.00256	CcSEcCtD
Torasemide—Leukopenia—Methotrexate—lymphatic system cancer	0.00149	0.00235	CcSEcCtD
Torasemide—Cough—Methotrexate—lymphatic system cancer	0.00145	0.00229	CcSEcCtD
Torasemide—Myalgia—Methotrexate—lymphatic system cancer	0.00142	0.00224	CcSEcCtD
Torasemide—Chest pain—Methotrexate—lymphatic system cancer	0.00142	0.00224	CcSEcCtD
Torasemide—Arthralgia—Methotrexate—lymphatic system cancer	0.00142	0.00224	CcSEcCtD
Torasemide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00133	0.0021	CcSEcCtD
Torasemide—Hypotension—Methotrexate—lymphatic system cancer	0.00127	0.002	CcSEcCtD
Torasemide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00124	0.00195	CcSEcCtD
Torasemide—Insomnia—Methotrexate—lymphatic system cancer	0.00123	0.00194	CcSEcCtD
Torasemide—Dyspepsia—Methotrexate—lymphatic system cancer	0.0012	0.00189	CcSEcCtD
Torasemide—Pain—Methotrexate—lymphatic system cancer	0.00116	0.00183	CcSEcCtD
Torasemide—Asthenia—Methotrexate—lymphatic system cancer	0.000976	0.00154	CcSEcCtD
Torasemide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000931	0.00147	CcSEcCtD
Torasemide—Dizziness—Methotrexate—lymphatic system cancer	0.0009	0.00142	CcSEcCtD
Torasemide—Vomiting—Methotrexate—lymphatic system cancer	0.000865	0.00136	CcSEcCtD
Torasemide—Rash—Methotrexate—lymphatic system cancer	0.000858	0.00135	CcSEcCtD
Torasemide—Dermatitis—Methotrexate—lymphatic system cancer	0.000857	0.00135	CcSEcCtD
Torasemide—Headache—Methotrexate—lymphatic system cancer	0.000852	0.00134	CcSEcCtD
Torasemide—Nausea—Methotrexate—lymphatic system cancer	0.000808	0.00127	CcSEcCtD
